Five Prime Therapeutics - Protein Medicines
Interview with Rusty Williams, MD, PhD, Executive Chairman and Founder; and Julia P. Gregory, President and CEO
on February 17, 2010
Essinova host BeiBei Song visits Five Prime Therapeutics, Inc. and speaks with its senior executives about the company's discovery platform, pipeline status, and strategic initiatives for 2010.
Five Prime Therapeutics, Inc. is a clinical-stage biotech company discovering innovative protein and antibody therapeutics using its unique discovery engine. The company's pipeline of biologics includes FP-1039, an oncology product in a phase 1 trial, and multiple preclinical and research programs in oncology, metabolic disease and immunology. The company uses its discovery platform to comprehensively screen secreted proteins and receptors using novel cell-based and in vivo screening systems.
Tags: Five Prime, Rusty Williams, Julia Gregory, proteins, peptides, extracellular proteome, protein therapeutics, FGF/FGFR, RIPPS, oncology, cancer, immunology, metabolic disease, diabetes, FP-1039